» Articles » PMID: 37609311

Noninvasive Molecular Subtyping of Pediatric Low-grade Glioma with Self-supervised Transfer Learning

Abstract

Purpose: To develop and externally validate a scan-to-prediction deep-learning pipeline for noninvasive, MRI-based BRAF mutational status classification for pLGG.

Materials And Methods: We conducted a retrospective study of two pLGG datasets with linked genomic and diagnostic T2-weighted MRI of patients: BCH (development dataset, n=214 [60 (28%) BRAF fusion, 50 (23%) BRAF V600E, 104 (49%) wild-type), and Child Brain Tumor Network (CBTN) (external validation, n=112 [60 (53%) BRAF-Fusion, 17 (15%) BRAF-V600E, 35 (32%) wild-type]). We developed a deep learning pipeline to classify BRAF mutational status (V600E vs. fusion vs. wildtype) via a two-stage process: 1) 3D tumor segmentation and extraction of axial tumor images, and 2) slice-wise, deep learning-based classification of mutational status. We investigated knowledge-transfer and self-supervised approaches to prevent model overfitting with a primary endpoint of the area under the receiver operating characteristic curve (AUC). To enhance model interpretability, we developed a novel metric, COMDist, that quantifies the accuracy of model attention around the tumor.

Results: A combination of transfer learning from a pretrained medical imaging-specific network and self-supervised label cross-training (TransferX) coupled with consensus logic yielded the highest macro-average AUC (0.82 [95% CI: 0.70-0.90]) and accuracy (77%) on internal validation, with an AUC improvement of +17.7% and a COMDist improvement of +6.4% versus training from scratch. On external validation, the TransferX model yielded AUC (0.73 [95% CI 0.68-0.88]) and accuracy (75%).

Conclusion: Transfer learning and self-supervised cross-training improved classification performance and generalizability for noninvasive pLGG mutational status prediction in a limited data scenario.

References
1.
Talloa D, Triarico S, Agresti P, Mastrangelo S, Attina G, Romano A . and MEK Targeted Therapies in Pediatric Central Nervous System Tumors. Cancers (Basel). 2022; 14(17). PMC: 9454417. DOI: 10.3390/cancers14174264. View

2.
Gillies R, Kinahan P, Hricak H . Radiomics: Images Are More than Pictures, They Are Data. Radiology. 2015; 278(2):563-77. PMC: 4734157. DOI: 10.1148/radiol.2015151169. View

3.
Nobre L, Zapotocky M, Ramaswamy V, Ryall S, Bennett J, Alderete D . Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. JCO Precis Oncol. 2020; 4. PMC: 7446502. DOI: 10.1200/PO.19.00298. View

4.
Kazmierski M, Welch M, Kim S, McIntosh C, Rey-McIntyre K, Huang S . Multi-institutional Prognostic Modeling in Head and Neck Cancer: Evaluating Impact and Generalizability of Deep Learning and Radiomics. Cancer Res Commun. 2023; 3(6):1140-1151. PMC: 10309070. DOI: 10.1158/2767-9764.CRC-22-0152. View

5.
Hosny A, Bitterman D, Guthier C, Qian J, Roberts H, Perni S . Clinical validation of deep learning algorithms for radiotherapy targeting of non-small-cell lung cancer: an observational study. Lancet Digit Health. 2022; 4(9):e657-e666. PMC: 9435511. DOI: 10.1016/S2589-7500(22)00129-7. View